Petros pharmaceuticals announces transition from nasdaq to otc markets

The company intends to appeal the delisting determination new york, ny / access newswire / may 21, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over the counter ("otc") drug development programs, today announces that it has received a staff determination letter from the nasdaq stock market, llc ("nasdaq"), informing the company that nasdaq determined to suspend trading and delist the company's common stock from nasdaq. at the open of trading on thursday, may 22, 2025, petros' securities will be suspended on nasdaq and are expected to begin trading on the otc markets under the ticker "ptpi".
PTPI Ratings Summary
PTPI Quant Ranking